Article
Medicine, General & Internal
Nicola Romano, Giammarco Baiardi, Valeria Maria Pinto, Sabrina Quintino, Barbara Gianesin, Riccardo Sasso, Andrea Diociasi, Francesca Mattioli, Roberta Marchese, Giovanni Abbruzzese, Antonio Castaldi, Gian Luca Forni
Summary: Neurodegeneration with brain iron accumulation (NBIA) is a group of rare diseases characterized by brain iron overload. Current treatment options only focus on symptom management. The use of deferiprone (DFP) appears to be a promising strategy for reducing iron accumulation and improving clinical symptoms.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Oncology
Artur Slomka, Monika Lecka, Jan Styczynski
Summary: This systematic review provides an overview of observational studies on the association between hepcidin and acute leukemia (AL) or hematopoietic cell transplantation (HCT). The review highlights the need for more extensive research as iron metabolism disturbances are common in AL and HCT, and hepcidin seems to play a significant role in their modulation.
Review
Multidisciplinary Sciences
Yesim Aydinok
Summary: Combination chelation therapy is a viable option for transfusion-dependent thalassemia patients who have not achieved iron balance with monotherapy or need intensified treatment for rapid iron reduction. It allows for a more personalized approach, improving tolerability, adherence, and quality of life. Real-life data highlights the importance of compliance in achieving meaningful reduction in iron overload compared to monotherapy.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
(2023)
Article
Multidisciplinary Sciences
Cornelia Knaak, Friederike S. Schuster, Peter Nyvlt, Patrick Heeren, Claudia Spies, Thomas Schenk, Paul La Rosee, Gritta Janka, Frank M. Brunkhorst, Gunnar Lachmann
Summary: This study found that transfusions, hemodialysis, and ECLS did not impact ferritin increases in critically ill patients. Changes in aspartate aminotransferase and sequential organ failure assessment score were identified as factors influencing ferritin change, with SOFA platelet count being associated with ferritin change in subgroups of SOFA score.
Article
Hematology
Richa Shah, Aashaka Shah, Sherif M. Badawy
Summary: Regular blood transfusions in thalassemia patients can lead to iron overload and related complications. Deferiprone, one of the FDA-approved iron chelators, is effective at reducing iron levels and has gained approval for twice-daily administration.
EXPERT REVIEW OF HEMATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Edouard Bardou-Jacquet, Houda Hamdi-Roze, Anita Paisant, Marie Decraecker, Marc Bourliere, Nathalie Ganne-Carrie, Victor de Ledinghen, Christophe Bureau
Summary: Increased serum ferritin is a common reason for referral, requiring thorough evaluation to avoid unnecessary exploration and inaccurate diagnosis. Factors and tools relevant to this situation must be known by clinicians. Magnetic resonance imaging is a reference method for accurately determining liver iron content.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
(2022)
Article
Nutrition & Dietetics
Lucia Iglesias-Vazquez, Victoria Arija, Nuria Aranda, Elom K. Aglago, Amanda J. Cross, Matthias B. Schulze, Daniel Quintana Pacheco, Tilman Kuhn, Elisabete Weiderpass, Rosario Tumino, Daniel Redondo-Sanchez, Maria Santucci de Magistris, Domenico Palli, Eva Ardanaz, Nasser Laouali, Emily Sonestedt, Isabel Drake, Lucia Rizzolo, Carmen Santiuste, Carlotta Sacerdote, Ramon Quiros, Pilar Amiano, Antonio Agudo, Paula Jakszyn
Summary: The study revealed that the prevalence of excess iron in European adults increases with latitude, with obesity, age, alcohol consumption, and heme iron intake being independent determinants for iron status.
EUROPEAN JOURNAL OF NUTRITION
(2022)
Article
Oncology
Yao Zhang, Chao Xiao, Jing Li, Lu-xi Song, You-shan Zhao, Shuang Han, Zhao-wei Li, Cha Guo, Jun-gong Zhao, Chun-kang Chang
Summary: DECT and MRI were complementary in liver iron detection, with DECT being more reliable than MRI in MDS patients with high iron content. MRI was more reliable than DECT in patients with low iron content. The appropriate detection method can be selected according to ASF for more accurate evaluation of iron content.
FRONTIERS IN ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Raffaella Mariani, Sara Pelucchi, Valentina Paolini, Michael Belingheri, Filiberto di Gennaro, Paola Faverio, Michele Riva, Alberto Pesci, Alberto Piperno
Summary: Prolonged exposure to welding fumes can lead to lung and liver issues, characterized by systemic iron overload and liver iron overload. Routine measurement of serum iron indices is recommended for welders to provide adequate diagnosis and therapy.
LIVER INTERNATIONAL
(2021)
Article
Clinical Neurology
Shalini S. Rao, Larissa Lago, Irene Volitakis, Jay J. Shukla, Gawain McColl, David I. Finkelstein, Paul A. Adlard
Summary: Iron dysregulation may contribute to the formation of neurofibrillary tangles in tauopathies, and the iron chelator DFP has shown potential therapeutic advantages in improving cognitive function and reducing tau protein aggregation in neurons.
Article
Medicine, General & Internal
Anna Spasiano, Antonella Meloni, Silvia Costantini, Emilio Quaia, Filippo Cademartiri, Patrizia Cinque, Alessia Pepe, Paolo Ricchi
Summary: The study indicates that a serum ferritin level <500 ng/mL is achievable and safe for certain TDT patients. This target is associated with the absence of significant cardiac iron overload, significantly lower hepatic IO, and triglycerides, both of which are well-demonstrated markers for cardiac and liver complications.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Hematology
Lap Shu Alan Chan, Lilly ChunHong Gu, Heather A. Leitch, Richard A. Wells
Summary: By measuring siROS levels in early hematopoietic cells of MDS patients, it was found that high blast MDS patients had lower siROS levels in their BM CD34+ cells, and a narrower siROS distribution, associated with increased reliance on glycolysis and ROS defense. There was a strong correlation between siROS levels in CD34+ cells and serum ferritin levels.
Article
Biochemistry & Molecular Biology
Clement Lahaye, Cecile Gladine, Bruno Pereira, Juliette Berger, Giulia Chinetti-Gbaguidi, Fabrice Lain, Andrzej Mazur, Marc Ruivard
Summary: In patients with DIOS, impairment in macrophage polarization towards the M2 alternative phenotype was observed, but it was not associated with a pro-inflammatory profile. Compared to MetS, DIOS patients showed an increased expression of several genes related to iron metabolism, with an upregulation of transferrin receptor 1 (TFRC) suggesting a potential adaptive role in limiting iron toxicity.
JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY
(2021)
Article
Nutrition & Dietetics
Aoibhin Moore Heslin, Aisling O'Donnell, Maria Buffini, Anne P. Nugent, Janette Walton, Albert Flynn, Breige A. McNulty
Summary: The study suggests that excessive adiposity is associated with disturbances in iron homeostasis, potentially leading to an increased risk of iron overload and implications for metabolic health.
Article
Oncology
Mathias Schneeweiss-Gleixner, Georg Greiner, Susanne Herndlhofer, Julia Schellnegger, Maria-Theresa Krauth, Karoline Gleixner, Friedrich Wimazal, Corinna Steinhauser, Michael Kundi, Renate Thalhammer, Ilse Schwarzinger, Gregor Hoermann, Harald Esterbauer, Manuela Fodinger, Peter Valent, Wolfgang R. Sperr
Summary: Although iron overload is a clinical challenge, little is known about the clinical impact of HFE-variants in myelodysplastic syndromes. The study found that HFE-variants H63D and C282Y are frequently detected in Austrian MDS patients, who have higher ferritin levels at diagnosis, accumulate iron slightly faster, and have a better progression-free survival than non-mutated patients.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Oncology
Miroslav Pribyl, Sona Hubackova, Alena Moudra, Marketa Vancurova, Helena Polackova, Tomas Stopka, Anna Jonasova, Radka Bokorova, Ota Fuchs, Jan Stritesky, Barbora Salovska, Jiri Bartek, Zdenek Hodny
MOLECULAR ONCOLOGY
(2020)
Article
Oncology
Guillermo Garcia-Manero, Valeria Santini, Antonio Almeida, Uwe Platzbecker, Anna Jonasova, Lewis R. Silverman, Jose Falantes, Gianluigi Reda, Francesco Buccisano, Pierre Fenaux, Rena Buckstein, Maria Diez Campelo, Stephen Larsen, David Valcarcel, Paresh Vyas, Valentina Giai, Esther Natalie Oliva, Jake Shortt, Dietger Niederwieser, Moshe Mittelman, Luana Fianchi, Ignazia La Torre, Jianhua Zhong, Eric Laille, Daniel Lopes de Menezes, Barry Skikne, C. L. Beach, Aristoteles Giagounidis
Summary: CC-486 significantly improved RBC-TI rate and induced durable bilineage improvements in patients with LR-MDS and high-risk disease features. However, more early deaths occurred in the CC-486 arm, most related to infections in patients with significant pretreatment neutropenia. Further evaluation of CC-486 in MDS is needed.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Pavla Koralkova, Monika Belickova, David Kundrat, Michaela Dostalova Merkerova, Zdenek Krejcik, Katarina Szikszai, Monika Kaisrlikova, Jitka Vesela, Pavla Vyhlidalova, Jan Stetka, Alzbeta Hlavackova, Jiri Suttnar, Patrik Flodr, Jan Stritesky, Anna Jonasova, Jaroslav Cermak, Vladimir Divoky
Summary: The study sheds light on the molecular network complexity underlying response/resistance to hypomethylating agents in MDS and AML-MRC, suggesting that the metabolic status and transcriptional characteristics of CD34(+) cells may be pivotal factors in predicting patient responses.
Article
Cell & Tissue Engineering
Lorena Lobo de Figueiredo-Pontes, Miroslava K. Adamcova, Srdjan Grusanovic, Maria Kuzmina, Izabela Aparecida Lopes, Amanda Fernandes de Oliveira Costa, Hong Zhang, Hynek Strnad, Sanghoon Lee, Alena Moudra, Anna T. Jonasova, Michal Zidka, Robert S. Welner, Daniel G. Tenen, Meritxell Alberich-Jorda
Summary: Research showed that donor natural killer (NK) cells negatively affect the frequency and function of hematopoietic stem cells (HSC), with interferon-gamma (IFNg) identified as a potential mediator. Improved HSC fitness was achieved by depleting NK cells or blocking IFNg activity from donor infusions.
Meeting Abstract
Hematology
Koichi Takahashi, Anna Jonasova, Selina M. Luger, Aref Al-Kali, David Valcarcel, Erica D. Warlick, Maria Diez-Campelo, Michael K. Keng, Feng Wang, Ken Furudate, Patrick S. Zbyszewski, Matthew Parris, Steven M. Fruchtman, Guillermo Garcia-Manero
Article
Oncology
Michaela Dostalova Merkerova, Jiri Klema, David Kundrat, Katarina Szikszai, Zdenek Krejcik, Andrea Hrustincova, Iva Trsova, Anh Vu Le, Jaroslav Cermak, Anna Jonasova, Monika Belickova
Summary: This study reveals that lncRNAs have the strongest predictive potential for AZA treatment. Through RNA sequencing analysis, a set of 14 lncRNAs and a few other genes and RNAs were identified as biomarkers for predicting the effectiveness of AZA treatment. The study also suggests the importance of epigenetic regulation and recombinational repair in AZA response.
CANCER GENOMICS & PROTEOMICS
(2022)
Article
Cell Biology
Lubomir Minarik, Kristyna Pimkova, Juraj Kokavec, Adela Schaffartzikova, Frederic Vellieux, Vojtech Kulvait, Lenka Daumova, Nina Dusilkova, Anna Jonasova, Karina Savvulidi Vargova, Petra Kralova Viziova, Radislav Sedlacek, Zuzana Zemanova, Tomas Stopka
Summary: Through the development of cellular models, researchers identified cancer-related pathways that play a crucial role in the resistance of myelodysplastic syndrome (MDS) cells to hypomethylating agents (HMA) and their progression to acute myeloid leukemia (AML). These pathways can be modulated by specific inhibitors, but do not increase the sensitivity of the cells to HMA.
Article
Oncology
Monika Kaisrlikova, Jitka Vesela, David Kundrat, Hana Votavova, Michaela Dostalova Merkerova, Zdenek Krejcik, Vladimir Divoky, Marek Jedlicka, Jan Fric, Jiri Klema, Dana Mikulenkova, Marketa Stastna Markova, Marie Lauermannova, Jolana Mertova, Jacqueline Soukupova Maaloufova, Anna Jonasova, Jaroslav Cermak, Monika Belickova
Summary: This study found that the RUNX1 mutation is the main predictor of rapid progression in LR-MDS patients. Comparison of gene expression profiles between patients with and without RUNX1 mutations suggests that RUNX1 mutations may trigger malignant transformation. Dysregulation of DDR and cellular senescence was also observed. Additionally, the expression profiles of RUNX1-mutated LR-MDS resemble those of higher-risk MDS.
Letter
Oncology
Tomas Stopka, Lubomir Minarik, Nina Dusilkova, Michal Pesta, Vojtech Kulvait, Martin Spacek, Zuzana Zemanova, Marta Kalousova, Anna Jonasova
BLOOD CANCER JOURNAL
(2022)
Article
Oncology
Anne Sophie Kubasch, Aristoteles Giagounidis, Georgia Metzgeroth, Anna Jonasova, Regina Herbst, Jose Miguel Torregrosa Diaz, Benoit De Renzis, Katharina S. Gotze, Marie-Luise Huetter-Kroenke, Marie-Pierre Gourin, Borhane Slama, Sophie Dimicoli-Salazar, Pascale Cony-Makhoul, Kamel Laribi, Sophie Park, Katja Jersemann, Dorothea Schipp, Klaus H. Metzeler, Oliver Tiebel, Katja Sockel, Silke Gloaguen, Anna Mies, Fatiha Chermat, Christian Thiede, Rosa Sapena, Richard F. Schlenk, Pierre Fenaux, Uwe Platzbecker, Lionel Ades
Summary: The study confirmed the safety and efficacy of ROM in LR-MDS patients, with SRSF2 mutation status and baseline hemoglobin levels significantly associated with hematologic improvement of platelets.
Meeting Abstract
Hematology
Anna Jonasova, Lubomir Minarik, Zuzana Zemanova, Helena Polackova, Tomas Stopka
Meeting Abstract
Oncology
Amy DeZern, Pierre Fenaux, Dries Deeren, Maria Diez Campelo, Michael Luebbert, Pramila Krishnamurthy, Zsolt Nagy, Grzegorz Basak, Anna Jonasova, Klaus Geissler, Yishai Ofran, Angela Volkert, Kristen Baker, Jaime Chisholm, Qing Kang-Fortner, David A. Roth, Michael Kelly, Giovanni Marconi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Meeting Abstract
Oncology
M. Kaisrlikova, J. Vesela, M. Vostry, H. Votavova, D. Kundrat, M. Dostalova Merkerova, M. Lauermannova, J. Soukupova Maaloufova, Z. Zemanova, A. Jonasova, J. Cermak, M. Belickova
Meeting Abstract
Oncology
M. Merkerova, J. Klema, D. Kundrat, Z. Krejcik, A. Hrustincova, I. Trsova, J. Cermak, A. Jonasova, M. Belickova
Meeting Abstract
Oncology
Z. Zemanova, J. Brezinova, K. Svobodova, H. Lhotska, T. Aghova, D. Vidlakova, S. Izakova, L. Lizcova, S. Ransdorfova, I. Mendlikova, L. Pavlistova, M. Belickova, J. Vesela, M. Siskova, R. Neuwirtova, J. Cermak, T. Stopka, A. Jonasova